EXTRAWELL PHAR (00858) intends to repurchase approximately 10.06% equity of Changchun Jingyou from Changchun Hando Dingye Real Estate Planning and Sales Co., Ltd. in Changchun City.
Jingyou Pharmaceuticals (00858) announced that on December 30, 2025, Longjing Jingyou (an indirect non-wholly-owned subsidiary in which the company holds an 80.46% equity interest) intends to repurchase approximately 10.06% of the equity interest in Longjing Jingyou from Changchun Hando Dingye Real Estate Planning and Sales Co., Ltd. for a consideration of 4.4 million RMB. After the repurchase of shares is completed, the repurchased shares will be cancelled, and the shareholder's equity interest in Longjing Jingyou will increase proportionally after the share cancellation, resulting in the Group's equity interest in Longjing Jingyou increasing to 89.46%. After the share repurchase and cancellation, Longjing Jingyou will continue to be an indirect non-wholly-owned subsidiary of the Group.
EXTRAWELL PHAR (00858) announces that on December 30, 2025, Changchun Jingyou (an indirect non-wholly owned subsidiary in which the company holds an 80.46% equity interest) plans to repurchase approximately 10.06% of the equity interest in Changchun Jingyou from Changchun Hando Tiange Real Estate Planning and Sales Co., Ltd. for a price of 4.4 million RMB. After the share repurchase is completed, the repurchased shares will be cancelled, and the shareholders' shareholding in Changchun Jingyou will increase proportionally after the share cancellation, thereby increasing the group's equity in Changchun Jingyou to 89.46%. After the share repurchase and share cancellation, Changchun Jingyou will continue to be an indirect non-wholly owned subsidiary of the group.
The board of directors believes that the share repurchase provides the group with an appropriate opportunity to further consolidate its control and ownership of Changchun Jingyou using the company's own cash resources, without affecting the normal business operations of Changchun Jingyou and the group. They anticipate that the share repurchase will enhance Changchun Jingyou's earnings per share.
Related Articles
ZHENGWEI GROUP (02147) plans to offer a discount of approximately 7.0% on the rights issue, with a net proceeds of approximately 87.1 million Hong Kong dollars.
US Stock Market Move | HSAI.US rose more than 3%, institutions predict that the market size of lidar and imaging radar will reach $28 billion by 2035.
RIZHAO PORT JR(06117): Jinfeng appointed as non-executive director.
ZHENGWEI GROUP (02147) plans to offer a discount of approximately 7.0% on the rights issue, with a net proceeds of approximately 87.1 million Hong Kong dollars.
US Stock Market Move | HSAI.US rose more than 3%, institutions predict that the market size of lidar and imaging radar will reach $28 billion by 2035.
RIZHAO PORT JR(06117): Jinfeng appointed as non-executive director.
